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Abstract 
Purpose: To evaluate the expression of EGFR, Ki67, and p-EPK in oral cavity and oropharyngeal 
cancers, and to investigate their clinical significance as prognostic markers. 
Methods: One hundred patients who underwent curative surgery for oral cavity or oropharyngeal 
squamous cell carcinoma in a Chinese People’s Liberation Army General Hospital between March 1999 
and October 2010 were evaluated. The level of protein expression of EGFR, Ki67 and p-EPK was 
assessed by immunohistochemistry. In situ hybridization was used to detect the existence of human 
papillomavirus (HPV). 
Results: Nineteen of 75 patients with oropharyngeal cancer showed HPV-positive tumors, and two of 
72 patients with oral cavity cancer showed HPV-positive tumors. EGFR and Ki67 expression was 
significantly higher in oral cavity cancers than in oropharyngeal cancers (p = 0.005 and p = 0.001, 
respectively). Loss of p-EPK occurred significantly more frequently in oral cavity cancers than in 
oropharyngeal cancers (p = 0.004). Overexpression of EGFR and Ki67 and loss of p-EPK were 
observed more frequently in HPV-negative tumors. Multivariate Cox regression analysis showed that 
Ki67 expression had a significantly unfavorable impact on relapse-free survival in oropharyngeal cancer. 
Conclusion: The expression levels of EGFR, Ki67, and p-EPK differ between oropharyngeal and oral 
cavity cancer and it may be attributed to HPV-related molecular pathogenesis. The expression of Ki67 
might be an unfavorable prognostic marker for relapse-free survival in oropharyngeal cancer. 
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Mucosal squamous cell carcinoma of the head 
and neck (SCCHN) comprises a heterogeneous 
group of tumors arising from the epithelial lining 
of the oral cavity, pharynx, and larynx. Despite 
distinct clinical characteristics, oral cavity cancer 
(OSCC) and oropharyngeal cancer (OPSCC) are 
frequently described as part of a group of oral 
cancers, and the two disease entities are often 
confused in the literature. OSCC includes the 
lips, buccal mucosa, teeth, gums, anterior two-
thirds of the tongue, floor of the mouth and hard 
palate. OPSCC includes the base of the tongue, 
soft palate, tonsils, and the lateral and posterior 
pharyngeal walls.  
 
In recent decades, studies have shown that 
OSCC and OPSCC have different incidence rate 
trends, etiology, and survival outcome [1]. For 
instance, human papillomavirus (HPV) is known 
as an important etiology for OPSCC, especially 
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tonsil cancer. However, there is little research on 
the differences in molecular pathogenesis 
between the two diseases. Aberrant epidermal 
growth factor receptor (EGFR) affects cell cycle 
progression, apoptosis, angiogenesis, and 
metastasis. EGFR is overexpressed in about 90 
% of all SCCHNs, and its overexpression 
correlates with poor prognosis [2]. The 
phosphatidylinositol 3-kinase (PI3K)/Akt pathway 
is important for cell survival because it promotes 
cell cycle progression and inhibits apoptosis [3]. 
Mammalian target of rapamycin (mTOR), a 
serine/threonine kinase and a downstream target 
of Akt, is important for the oncogenic 
transformation induced by PI3K and Akt. 
Signaling through the PI3K/Akt/mTOR pathway is 
activated by growth factor ligand binding to 
receptor tyrosine kinases and regulates several 
cellular functions that are critical for 
tumorigenesis. The p-EPK, a tumor suppressor 
gene, negatively regulates the PI3K/Akt pathway. 
The loss of p-EPK function causes increased 
Ki67 activity and continued cell survival and 
proliferation [4]. In this study, we evaluated the 
expression of EGFR, Ki67 and p-EPK in OSCC 
and OPSCC, and investigated their clinical 






One hundred patients who underwent curative 
surgery for OPSCC or OSCC in Chinese 
People’s Liberation Army General Hospital 
between March 1999 and October 2010 were 
evaluated. Among the 100 patients, 51 (51.0 %) 
had been diagnosed with OPSCC and 49 (49.0 
%) with OSCC. Clinical records and pathology 
reports were reviewed retrospectively. The 
following clinical data were collected: age, sex, 
smoking history, tumor staging, surgery type, 
chemotherapy, radiotherapy, recurrence, and 
survival. Ethical committee approval (ref no. 
201406005) was obtained from the Institutional 
Review Board of Beijing University. Informed 
consent was provided according to the 
Declaration of Helsinki. 
 
In situ hybridization for HPV 
 
In situ hybridization was processed on the 
automated Benchmark system from Ventana 
Medical Systems using INFORM HPV III Family 
16 Probe (cocktail of HPV subtypes 16, 18, 31, 
33, 35, 39, 45, 51, 52, 56, and 66, Ventana 
Medical Systems) as per the manufacturer’s 
recommendations. This system removes the 
paraffin wax from the tissue, subjects it to 
protease digestion, and then hybridizes the 
tissue with a probe. The probe–target complex is 
detected because of the action of alkaline 
phosphatase on chromogen nitroblue tetrazolium 
and bromochloroindolyl phosphate, which yields 
a dark-blue color with a pink counterstain for the 
HPV-negative cells caused by nuclear fast red 
staining. The signal patterns of HPV in the nuclei 
were classified as follows: diffuse, signals that 
were condensed and uniformly packed in the 
nucleus; punctate, signals that were dot-like and 




Overall survival (OS) was defined as the time 
from the date of diagnosis to the date of death or 
last follow-up. Relapse-free survival (RFS) was 
defined as the time from surgery to disease 
recurrence. Continuous and categorical variables 
were compared using Student’s t test and the 
chi-square test. Univariate analysis and survival 
curves were estimated using the Kaplan–Meier 
method, and the log-rank test was applied to 
identify differences. Multivariate analysis was 
performed with Cox hazards regression model. 
All statistical analyses were performed using 







The clinicopathological characteristics of the 100 
patients are summarized in Table 1. The mean 
age of the patients was 52.8 (range 25 – 90) 
years. Among the 51 OPSCC patients, 48 (78.7 
%) patients had tonsil cancer, 9 (14.7 %) patients 
had cancer of the base of the tongue, 2 (3.3 %) 
patients had soft palate cancer, and 2 (3.3 %) 
patients had pharyngeal wall cancer. Among the 
49 OSCC patients, 51 (85.0 %) patients had 
tongue cancer, 5(8.3 %) patients had buccal 
mucosa cancer, and 4 (6.7 %) patients had 
cancer of the floor of the mouth. The percentage 
of men was higher in those with OPSCC (93.4 
%) than in those with OSCC (63.3 %, p = 0.001). 
19 (31.1 %) of 61 patients with OPSCC showed 
HPV-positive tumors, and only 2(3.3 %) of 60 
patients with OSCC showed HPV-positive tumors 
(p = 0.001). Well-differentiated histological type 
was more frequent in OSCC than in OPSCC (p = 
0.001). Cervical lymph node metastasis with 
advanced N stage was more frequent in OPSCC 
than in OSCC (p = 0.002). Adjuvant therapy after 
surgery was followed more frequently in OPSCC 
than in OSCC (p = 0.031). Age, smoking history, 
and T stage did not differ significantly between 
patients with OPSCC and OSCC. 
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Immunohistochemical staining and 
correlation analysis 
 
The results of immunohistochemical staining are 
listed in Table 2. EGFR and Ki67 expression was 
significantly higher in OSCC than in OPSCC (p = 
0.005 and p = 0.001, respectively). Loss of p-
EPK was more frequent in OSCC than in 
OPSCC (p = 0.004). Overexpression of EGFR 
and Ki67 was observed more frequently in HPV-
negative tumors than in HPV-positive tumors (p = 
0.003 and p = 0.037, respectively). Loss of p-
EPK was observed more frequently in HPV-
negative tumors than in HPV-positive tumors (p = 
0.001). Ki67 overexpression and loss of p-EPK 
occurred more frequently in tumors with well-
differentiated histology (p = 0.003 and p = 0.006, 
respectively). We analyzed the individual 
relationships between EGFR, Ki67 and p-EPK 
expression. p-EPK and Ki67 expression 
correlated inversely(p = 0.032). Other variables 
did not correlate significantly. 
 
 
Table 1: Clinicopathological characteristics of oropharyngeal and oral cavity cancer patients 
 
Variable All patients (n =100)   
OPSCC 
(n =51)   
OSCC 
(n = 49)   
   
p-value 
  No.(%) No.(%) No.(%)   
Age (years)        Mean±SD 52.8±9.4 53.5±8.7 52.4±11.2 0.608 
Sex    0.001    Men 72(72.0) 48(94.1) 36(73.5)     Women 28(28.0) 3(5.9) 13(26.5)  Smoking    0.672    Former or current 71(71.0) 32(62.7) 32(65.3)     Non-smoker 29(29.0) 19(37.3) 17(34.7)  HPV status    0.001    Positive 25(25.0) 16(31.4) 4(8.3)     Negative 75(75.0) 35(68.6) 45(91.8)  Histologic grade    0.001    Well 31(31.0) 10(20.0) 28(57.1)     Moderate 56(56.0) 32(62.7) 15(30.6)     Poor 13(13.0) 8(17.3) 7(14.3)  T stage    0.057    < 2 cm 32(32.0) 10(20) 21(42.9)     》2 cm, < 4 cm 59(59.0) 33(64.7) 24(49.0)  
   》4 cm 9(9.0) 7(15.3) 5(10.2)  N stage    0.003    N0 51(51.0) 9(17.6) 27(55.1)     N1 13(13.0) 8(15.7) 8(16.3)     N2a 3(3.0) 3(5.9) 2(4.1)     N2b 27(27.0) 14(27.5) 9(18.4)     N2c 6(6.0) 16(31.4) 4(8.2)  Treatment        Surgery alone 36(36.0) 14(27.5) 24(49.0) 0.028 
   Adj RT 31(31.0) 21(41.2) 14(28.6) 0.079 
   Adj CCRT 22(22.0) 10(19.6) 7(14.3) 0.459 
   Adj CTx 11(11.0) 5(9.8) 5(10.2) 0.321 
 
Table 2: Immunohistochemical staining for EGFR, Ki67 and p-EPK 
 
Variable  All patients  (n = 100) 
OPSCC 
(n = 51) OSCC (n = 49) p-value 
  No.(%) No.(%) No.(%)  EGFR    0.006      Positive 63(63.0) 28(54.9) 31(63.3)       Negative 37(37.0) 23(45.1) 18(36.7)  Ki67    0.004      Positive 12(8.9) 21(17.9) 25(26.6)       Negative 85(91.1) 18(56.7) 22(47.5)  p-EPK    0.201      Positive 64(65.6) 32(74.2) 24(47.2)       Negative 29(34.4) 18(20.8) 17(31.6)  
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Carcinomas of the oropharynx and oral cavity 
constitute 2 – 5 % of SCCHNs. In the past, 
OPSCC and OSCC were considered types of 
oral cancers with the same etiology including 
smoking and alcohol abuse. However, there is 
growing evidence to support the idea that 
OPSCC and OSCC are two distinct diseases 
with different etiologies [5].  
 
Since the 1980s, evidence has been emerging 
that HPV is an etiological factor for a subset of 
OPSCC [6]. Previous studies reported that the 
rate of HPV positivity is higher in OPSCC, 
especially tonsil cancer, than in OSCC [7]. Our 
result is consistent with these previous results: 
about 30 % of OPSCC patients showed HPV 
positivity, in contrast to 3 % of OSCC patients. 
 
We compared the expression of the EGFR and 
Ki67/p-EPK pathway, which is crucial for cell 
survival and growth, in OPSCC and OSCC 
patients. EGFR and Ki67 expression was 
significantly higher in OSCC than in OPSCC, and 
loss of p-EPK occurred more frequently in OSCC 
than in OPSCC.  
 
The correlation analysis between the expression 
of these proteins and HPV status showed that 
overexpression of EGFR and Ki67 and loss of p-
EPK were observed more frequently in HPV-
negative tumors. Therefore, these differences in 
EGFR, Ki67 and p-EPK expression between 
OPSCC and OSCC may be attributed to HPV-
related molecular pathogenesis. 
 
Previous studies showed that Ki67 expression is 
associated with poor outcome in OPSCC and 
OSCC. Massarelli et al reported that tongue 
cancer patients with Ki67 expression showed 
significantly shorter disease-free survival [8]. Yu 
et al reported that OPSCC patients with a low 
Ki67 level had a lower 5-year local recurrence 
rate and better 5-year overall survival rate [9].  
 
However, research on the relationship between 
Ki67 expression and HPV status is limited. In the 
present study, Ki67 overexpression was 
significantly lower in HPV-positive tumors than in 
HPV-negative tumors. Analysis of RFS showed 
that T and N stages were only meaningful as a 
prognostic factor in OSCC patients. Meanwhile, 
OPSCC patients with Ki67 overexpression 
tended to have a lower 3-year RFS rate, and in 
patients with tonsil cancer, the overexpression of 





The findings of this study reveal that Ki67 may be 
a prognostic marker for RFS in OPSCC patients, 
especially in those with tonsil cancer. Further 
studies are needed to identify more clearly the 
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